Alnylam Pharmaceuticals reached
free cash flow breakeven in 2025, with a 1.13%
earnings yield. Recent developments highlight
Vutrisiran outcomes and
Zilebesiran safety data. The company recently reported its
Q4 2025 results and has exhibited strong growth. A strategic collaboration with
Viz.ai and
American Heart Association, focus on
cardiovascular data, and progress in
RNAi pipeline potential underscore its commitment to innovation.
Financial & partnership announcements include recent auto-sale of shares by HR and a
$1.23bn deal with Tenaya for cardiovascular target discovery. The company is expanding its footprint with a
$250M investment in Norton. Despite recent share price weakness, the company maintained
bullish fair value. The company's
2025 revenue hit $3B driven by a 151% TTR franchise surge, projecting
2026 revenue around $5.3 billion as it focuses on a new five-year strategy. Analyst views diverge on target revenue and long-term growth. Is Alnylam Pharmaceuticals one of the best high growth healthcare stocks to buy now?
Alnylam Pharmaceuticals News Analytics from Fri, 01 Aug 2025 07:00:00 GMT to Sat, 11 Apr 2026 13:14:34 GMT -
Rating 7
- Innovation 8
- Information 7
- Rumor -5
